The global therapeutic vaccines market is estimated to grow from USD 11.0 billion in the current year to USD 86.8 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 25.8% during the forecast period.
For much of the past two decades, the therapeutic melanoma vaccine field has been driven by considerable clinical interest, however, despite significant advances in melanoma immunotherapy, no therapeutic melanoma vaccine has yet received full USFDA approval. That gap between promise and product is now narrowing. More than 400 cancer vaccine clinical trials are currently active worldwide, and over 300 cancer vaccine candidates are currently being developed for a broad range of oncological indications, supported by steady advances in adjuvant science and formulation stability.
A defining shift in the space is the move toward next generation neoantigen mRNA vaccines. Built on genomic sequencing, bioinformatics, and personalized-medicine platforms, these candidates are designed against a patient's own tumor-specific neoantigens rather than shared antigens, improving precision and immune activation relative to earlier cancer vaccine generations. Recently, Moderna and Merck jointly reported that their investigational personalized cancer vaccine, used alongside Keytruda, sustained a meaningful reduction in recurrence or death risk in melanoma patients. These clinical results are reinforcing confidence in this approach and drawing continued capital toward the neoantigen and mRNA vaccine segment.
Parallel advances in immuno-oncology and vaccine engineering, including DNA and mRNA platforms, improved adjuvants, next-generation vectors, and neoantigen-based design, are enabling vaccines that generate stronger and more targeted T-cell responses. These platforms are also easier to customize for individual tumors or patients, aligning naturally with the broader industry shift toward precision medicine and reinforcing sustained R&D investment in the category.
Development itself is technically demanding. Sponsors must select the right antigens, delivery systems, adjuvants, and dosing regimens while safeguarding safety and efficacy, a process that carries a high rate of candidate attrition. Trial design is further complicated by diverse tumor types and disease stages across enrolled repeated late-stage setbacks have periodically dampened investor sentiment, slowing pipeline advancement for smaller developers in particular.
On the other hand, the DNA vaccines segment is projected to grow at a higher CAGR during the forecast period. This potential growth is supported by advances in genetic engineering and rising demand for next-generation vaccine platforms. DNA vaccines offer rapid design cycles, manufacturing flexibility, and the ability to trigger both humoral and cellular immunity, and growing investment in genomic medicine and precision immunotherapy is expected to accelerate their uptake.
The infectious diseases segment is expected to grow fastest CAGR during the forecast period. This lucrative growth is driven by growing interest in therapeutic vaccines for chronic and difficult-to-treat viral and bacterial infections. Advances in DNA, RNA, and vector-based platforms are enabling novel approaches that strengthen immune response and reduce reliance on long-term antimicrobial therapy.
Asia-Pacific is projected to grow at the fastest CAGR during the forecast period. This lucrative growth is driven by rising healthcare expenditure, expanding biopharmaceutical research capacity, and a growing burden of cancer and infectious disease across China, India, Japan, and South Korea. Increasing government support for biotechnology innovation and improving clinical infrastructure are creating favorable conditions for accelerated regional expansion.
Therapeutic Vaccines Market: Growth and Trends
Unlike prophylactic vaccines, which are administered to healthy individuals to prevent disease, therapeutic vaccines are designed to be given after a disease has already taken hold, with the goal of training the immune system to recognize and act against it. Their efficacy generally trails that of prophylactic formulations, but they offer a safety, specificity, and durability profile that has made them an attractive modality for oncology and chronic infectious disease, and they are also being explored for individuals whose own antibody response is insufficient to control an existing infection.For much of the past two decades, the therapeutic melanoma vaccine field has been driven by considerable clinical interest, however, despite significant advances in melanoma immunotherapy, no therapeutic melanoma vaccine has yet received full USFDA approval. That gap between promise and product is now narrowing. More than 400 cancer vaccine clinical trials are currently active worldwide, and over 300 cancer vaccine candidates are currently being developed for a broad range of oncological indications, supported by steady advances in adjuvant science and formulation stability.
A defining shift in the space is the move toward next generation neoantigen mRNA vaccines. Built on genomic sequencing, bioinformatics, and personalized-medicine platforms, these candidates are designed against a patient's own tumor-specific neoantigens rather than shared antigens, improving precision and immune activation relative to earlier cancer vaccine generations. Recently, Moderna and Merck jointly reported that their investigational personalized cancer vaccine, used alongside Keytruda, sustained a meaningful reduction in recurrence or death risk in melanoma patients. These clinical results are reinforcing confidence in this approach and drawing continued capital toward the neoantigen and mRNA vaccine segment.
Growth Drivers: Factors Fueling Market Expansion
The rising global burden of cancer, together with the persistence of chronic infectious diseases such as HIV, HBV, and HCV, is a central driver of this market. These conditions typically involve prolonged disease courses, high relapse rates, and significant treatment costs, creating a clear clinical case for durable immune-based therapies. As screening and diagnostic capabilities improve across geographies, more patients are being identified early enough for therapeutic vaccination to be incorporated into their treatment plans, widening the addressable patient pool.Parallel advances in immuno-oncology and vaccine engineering, including DNA and mRNA platforms, improved adjuvants, next-generation vectors, and neoantigen-based design, are enabling vaccines that generate stronger and more targeted T-cell responses. These platforms are also easier to customize for individual tumors or patients, aligning naturally with the broader industry shift toward precision medicine and reinforcing sustained R&D investment in the category.
Market Challenges: Critical Barriers Hindering Progress
Despite this momentum, therapeutic vaccines continue to face a translational gap between preclinical promise and real-world patient outcomes. Human immune responses, particularly in complex diseases such as cancer, are harder to control than in laboratory or animal models, and tumor and patient heterogeneity mean that a vaccine effective in one individual may perform poorly in another. This variability makes it difficult to demonstrate consistent, statistically robust benefit in clinical trials, and correspondingly difficult to displace established standard-of-care therapies.Development itself is technically demanding. Sponsors must select the right antigens, delivery systems, adjuvants, and dosing regimens while safeguarding safety and efficacy, a process that carries a high rate of candidate attrition. Trial design is further complicated by diverse tumor types and disease stages across enrolled repeated late-stage setbacks have periodically dampened investor sentiment, slowing pipeline advancement for smaller developers in particular.
Therapeutic Vaccines Market: Key Insights
The report delves into the current state of the therapeutic vaccines market and identifies potential growth opportunities within the industry. Some key findings include:
- Platform Flexibility Driving mRNA Expansion Across Oncology and Rare Diseases: Driven by the platform’s inherent flexibility, high immunogenicity, and the pressing need for targeted treatment options, an expanding base of biopharmaceutical innovators and large pharmaceutical companies is prioritizing mRNA-based drug development across complex oncology and rare disease indications.
- Pipeline Concentration Among Industry Trailblazers: Over 300 therapeutic vaccine candidates are under active investigation across various stages of clinical development. Notably, approximately 70% of active pipeline activity remains concentrated among market leaders Moderna and BioNTech, underscoring an intense consolidation of developer expertise.
- Accelerating Strategic Alliances Between Platform Owners and Indication Specialists: Deal flow targeting novel disease mechanisms continues to gather momentum. For instance, Moderna partnered with Recordati to advance mRNA-3927, its investigational mRNA candidate for propionic acidemia, through development and toward eventual commercialization.
- Robust Early-Stage Venture Capital and Seed Funding Inflows: Private equity and venture investments into mRNA-focused platforms have risen steadily, providing companies with crucial runway to advance candidates toward pivotal clinical evaluations. Early-stage funding reflects this trend: Reprogram Biosciences raised USD 6 million in seed funding in May to advance its proprietary mRNA-based in situ cell reprogramming approach designed to transform tumor beds into active antigen-presenting sites. Additionally, ErVimmune closed a €17 million Series A to push its therapeutic cancer vaccine ErVac01 into human trials.
- Clinical Maturity and Late-Stage Advancement: More than 10% of the global therapeutic vaccines pipeline has reached Phase III, reflecting an unusually high late-stage proportion for an emerging biological modality. While this signals growing regulatory acceptance and clinical maturity, overall pipeline leadership remains heavily anchored by first-mover pioneers.
- Shift Toward M&A and Licensing Over In-House Platform Development: Rather than constructing internal mRNA capabilities from scratch, large pharmaceutical incumbents are actively acquiring or entering deep collaboration agreements with specialized RNA developers. Pfizer leads this trend through multi-target platform alliances, followed by Sanofi (which expanded its core RNA infrastructure via the acquisition of Translate Bio), and Bayer, which continues to enter targeted clinical collaborations.
Therapeutic Vaccines Market
The market sizing and opportunity analysis has been segmented across the following parameters:By Type of Vaccine
- Peptide Vaccines
- Antigen Vaccines
- DNA Vaccines
- Dendritic Vaccines
By Method of Vaccine Composition
- Autologous Vaccines
- Allogeneic Vaccines
By Type of Therapy
- Monotherapies
- Combination Therapies
By Therapeutic Area
- Oncological Disorders
- Infectious Diseases
- Autoimmune Disorders
- Others
By Route of Administration
- Intradermal Route
- Intramuscular Route
- Subcutaneous Route
- Intranasal Route
- Oral Route
- Others
By Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
Therapeutic Vaccines Market: Key Segments
Peptide Vaccines Lead the Market and DNA Vaccines Will Register Higher CAGR
Based on our market assessment, the peptide vaccines segment is expected to account for the largest share of the therapeutic vaccines market. This highest share is due to its high specificity, safety profile, and broad applicability across cancer immunotherapy and infectious disease treatment. These vaccines rely on selected antigenic peptides to stimulate targeted immune responses against disease-associated markers. Owing to their target specificity, these vaccines limit off-target effects and improve treatment outcomes. Further, their relatively simple design and manufacturing scalability have supported wide clinical adoption.On the other hand, the DNA vaccines segment is projected to grow at a higher CAGR during the forecast period. This potential growth is supported by advances in genetic engineering and rising demand for next-generation vaccine platforms. DNA vaccines offer rapid design cycles, manufacturing flexibility, and the ability to trigger both humoral and cellular immunity, and growing investment in genomic medicine and precision immunotherapy is expected to accelerate their uptake.
Oncological Disorders Dominate the Market
Oncological disorders account for the largest share of the therapeutic vaccines market. This highest share reflects the global cancer burden and the growing role of therapeutic vaccination as an immunotherapy approach that stimulates the immune system to target tumor-specific antigens. Sustained investment in cancer research, a deepening pipeline of vaccine candidates, and closer integration with other immuno-oncology modalities continue to accelerate clinical development and eventual commercialization in this segment.The infectious diseases segment is expected to grow fastest CAGR during the forecast period. This lucrative growth is driven by growing interest in therapeutic vaccines for chronic and difficult-to-treat viral and bacterial infections. Advances in DNA, RNA, and vector-based platforms are enabling novel approaches that strengthen immune response and reduce reliance on long-term antimicrobial therapy.
North America Maintains Market Leadership
According to our market projections, North America is expected to hold the majority share of the market in the current year. This highest share is supported by the advanced healthcare infrastructure, a strong biotechnology and pharmaceutical base, and substantial investment in immunotherapy R&D. Further, the region's mature clinical trial ecosystem, favorable regulatory pathways, and high prevalence of cancer and other chronic conditions continue to reinforce its lead position.Asia-Pacific is projected to grow at the fastest CAGR during the forecast period. This lucrative growth is driven by rising healthcare expenditure, expanding biopharmaceutical research capacity, and a growing burden of cancer and infectious disease across China, India, Japan, and South Korea. Increasing government support for biotechnology innovation and improving clinical infrastructure are creating favorable conditions for accelerated regional expansion.
Example Players in Therapeutic Vaccines Market
- BioNTech
- GlobeImmune
- Immatics
- Immunitor
- Inovio Pharmaceuticals
- Moderna
Expert Interview and Industry Insights
The opinions and insights presented in this study were shaped by discussions held with multiple stakeholders across the therapeutic vaccines value chain. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:- Chief Executive Officer and Chief Scientific Officer, Mid-sized Company, Italy
- Science Director Advanced Modalities, Senior Research Leader, and Director of Scientific Advisory Services, Very Large Company, US
- Director of Head and Neck Cancer Research, Very Large Company, US
- Associate Professor of Surgery, Integrative Immunology, and Pathology, Very Large Institute, US
- Physician Scientists, Very Large Institute, US
- Pediatric Oncologist, Very Large Institute, US
- Associate Director for Translational Research, Very Large Institute, US
- Research Group Leader, Mid-sized Institute, Germany
- Senior Public Health Researcher, Mid-sized Institute, India
THERAPEUTIC VACCINES MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: In-depth analysis of the therapeutic vaccines market across type of vaccine, method of vaccine composition, type of therapy, therapeutic area, route of administration, and geographical regions.
- Market Landscape: A detailed pipeline assessment by phase of development, vaccine type, therapy type, therapeutic area, route of administration, and dosage, together with an analysis of vaccine developers by year of establishment, company size, and location of headquarters.
- Company Profiles: In-depth profiles of prominent players engaged in developing therapeutic vaccines, covering year of establishment, headquarters, company size, financial information, portfolio, and recent developments.
- Start-Up Health Indexing: Benchmarking of emerging vaccine developers by supplier strength, pipeline strength, pipeline maturity, financial investment, and partnership activity.
- Clinical Trial Analysis: An analysis of registered clinical trials by registration year, phase, recruitment status, study design, focus area, therapeutic area, sponsor type, and geography.
- Academic Grants Analysis: Assessment of research grants by year of award, amount awarded, administering institute, support period, and recipient organization.
- Partnerships and Collaborations: A review of deal activity by year, type of partnership, type of partner, focus area, therapeutic area, and geographical distribution.
- Market Forecast and Opportunity Analysis: Ten-year revenue forecasts for the global market and its sub-segments, together with country-level projections across twelve key markets.
- Case Study, Preventive Vaccines Market: A comparative view of the marketed and clinical-stage preventive vaccines landscape, positioned as an adjacent-market benchmark for the therapeutic vaccines.
- Case Study, Vaccine Contract Manufacturing Market: An overview of the vaccine CMO landscape by scale of operation, service offering, and expression system, relevant to distributors assessing supply-chain partners.
Key Questions Answered in this Report
- Which companies are leading the therapeutic vaccines market?
- Which region dominates the therapeutic vaccines market?
- What are the key trends observed in the therapeutic vaccines market?
- What factors are likely to influence the evolution of this market?
- What are the primary challenges faced by therapeutic vaccine developers?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
- The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
- The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
- The report allows for more effective communication with the audience and in building strong business relations.
Additional Benefits
- Complementary PPT Data Packs
- Complementary Excel Data Packs for all Analytical Modules in the Report
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. PREFACE
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
6. INTRODUCTION
7. MARKET LANDSCAPE
8. COMPANY PROFILES
9. START-UP HEALTH INDEXING
10. CLINICAL TRIAL ANALYSIS
11. ACADEMIC GRANTS ANALYSIS
12. PARTNERSHIPS AND COLLABORATIONS
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14. CASE STUDY: GLOBAL PREVENTIVE VACCINES
15. CASE STUDY: VACCINE CONTRACT MANUFACTURING MARKET
17. EXECUTIVE INSIGHTS
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioNTech
- GlobeImmune
- Immatics
- Immunitor
- Inovio Pharmaceuticals
- Moderna
Methodology
LOADING...
